Michael J Pencina

List of Publications by Year
in descending order

199 papers	**46,200** citations	6613 **79** h-index
201 all docs	**201** docs citations	**201** times ranked

2629 **194** g-index
55057 citing authors

#	Article	IF	Citations
1	General Cardiovascular Risk Profile for Use in Primary Care. Circulation, 2008, 117, 743-753.	1.6	5,601
2	Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Statistics in Medicine, 2008, 27, 157-172.	1.6	5,331
3	Assessing the Performance of Prediction Models. Epidemiology, 2010, 21, 128-138.	2.7	3,387
4	Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation, 2008, 117, 503-511.	1.6	2,077
5	Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statistics in Medicine, 2011, 30, 11-21.	1.6	1,989
6	Arterial Stiffness and Cardiovascular Events. Circulation, 2010, 121, 505-511.	1.6	1,824
7	Comments on 'Integrated discrimination and net reclassification improvements—Practical advice'. Statistics in Medicine, 2008, 27, 207-212.	1.6	1,299
8	OverallC as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statistics in Medicine, 2004, 23, 2109-2123.	1.6	1,264
9	One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2007, 297, 1197.	7.4	1,162
10	On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Statistics in Medicine, 2011, 30, 1105-1117.	1.6	972
11	Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet, The, 2009, 373, 739-745.	13.7	883
12	Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve. Circulation, 2011, 124, 2215-2224.	1.6	710
13	Predicting the 30-Year Risk of Cardiovascular Disease. Circulation, 2009, 119, 3078-3084.	1.6	688
14	Carotid-Wall Intima–Media Thickness and Cardiovascular Events. New England Journal of Medicine, 2011, 365, 213-221.	27.0	678
15	Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE-AF Consortium. Journal of the American Heart Association, 2013, 2, e000102.	3.7	601
16	Application of New Cholesterol Guidelines to a Population-Based Sample. New England Journal of Medicine, 2014, 370, 1422-1431.	27.0	571
17	Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus. Circulation, 2007, 115, 1544-1550.	1.6	567
18	Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 2009, 119, 1728-1735.	1.6	507

#	Article	IF	Citations
19	Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women. JAMA - Journal of the American Medical Association, 2007, 298, 776.	7.4	496
20	Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. Journal of the American College of Cardiology, 2012, 60, 1249-1256.	2.8	496
21	Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. JAMA - Journal of the American Medical Association, 2009, 302, 49.	7.4	474
22	A calibration hierarchy for risk models was defined: from utopia to empirical data. Journal of Clinical Epidemiology, 2016, 74, 167-176.	5.0	473
23	Net Reclassification Improvement: Computation, Interpretation, and Controversies. Annals of Internal Medicine, 2014, 160, 122-131.	3.9	453
24	Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction. Circulation, 2008, 118, 2057-2062.	1.6	428
25	Interpreting Incremental Value of Markers Added to Risk Prediction Models. American Journal of Epidemiology, 2012, 176, 473-481.	3.4	397
26	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of Clinical Lipidology, 2007, 1, 583-592.	1.5	365
27	Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s. Circulation, 2006, 113, 2914-2918.	1.6	340
28	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	7.4	313
29	Statistical methods for assessment of added usefulness of new biomarkers. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1703-1711.	2.3	287
30	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation, 2015, 131, 451-458.	1.6	283
31	Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 304, 2263.	7.4	257
32	Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Statistics in Medicine, 2012, 31, 101-113.	1.6	250
33	Relations of Thyroid Function to Body Weight<subtitle>Cross-sectional and Longitudinal Observations in a Community-Based Sample</subtitle>. Archives of Internal Medicine, 2008, 168, 587.	3.8	249
34	Impact of Impaired Fasting Glucose on Cardiovascular Disease. Journal of the American College of Cardiology, 2008, 51, 264-270.	2.8	248
35	Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community. Circulation, 2010, 121, 200-207.	1.6	243
36	A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study. Annals of Internal Medicine, 2008, 148, 102.	3.9	240

#	ARTICLE	IF	CITATIONS
37	Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. Circulation, 2009, 120, 212-220.	1.6	223
38	Association of Smoking Cessation and Weight Change With Cardiovascular Disease Among Adults With and Without Diabetes. JAMA - Journal of the American Medical Association, 2013, 309, 1014.	7.4	216
39	Sibling Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults. JAMA - Journal of the American Medical Association, 2005, 294, 3117.	7.4	213
40	Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry). Circulation, 2012, 126, 304-313.	1.6	202
41	A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium. Circulation: Cardiovascular Genetics, 2012, 5, 113-121.	5.1	196
42	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
43	Misuse of DeLong test to compare AUCs for nested models. Statistics in Medicine, 2012, 31, 2577-2587.	1.6	192
44	Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men. Annals of Internal Medicine, 2006, 145, 176.	3.9	188
45	Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors. Circulation, 2007, 116, 984-992.	1.6	185
46	Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study. Diabetes Care, 2008, 31, 1582-1584.	8.6	184
47	An International Model to Predict Recurrent Cardiovascular Disease. American Journal of Medicine, 2012, 125, 695-703.e1.	1.5	184
48	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	7.4	179
49	Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Medical Genetics, 2007, 8, S13.	2.1	171
50	Increasing Trends in Incidence of Overweight and Obesity over 5 Decades. American Journal of Medicine, 2007, 120, 242-250.e2.	1.5	168
51	Longitudinal Tracking of Left Ventricular Mass Over the Adult Life Course. Circulation, 2009, 119, 3085-3092.	1.6	168
52	Association of Parental Heart Failure with Risk of Heart Failure in Offspring. New England Journal of Medicine, 2006, 355, 138-147.	27.0	166
53	Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50 Years Using 40 Type 2 Diabetes Risk Single Nucleotide Polymorphisms. Diabetes Care, 2011, 34, 121-125.	8.6	165
54	Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. European Journal of Clinical Investigation, 2012, 42, 216-228.	3.4	165

#	ARTICLE	IF	CITATIONS
55	Embolic Protection and Platelet Inhibition During Renal Artery Stenting. Circulation, 2008, 117, 2752-2760.	1.6	163
56	Rationale and design of the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An) Tj ETQq0 0 0 rgBT /Overlock 10	1.3	152
57	Common Carotid Artery Intima-Media Thickness Progression as a Predictor of Stroke in Multi-Ethnic Study of Atherosclerosis. Stroke, 2011, 42, 3017-3021.	2.0	149
58	Choice of time scale and its effect on significance of predictors in longitudinal studies. Statistics in Medicine, 2007, 26, 1343-1359.	1.6	147
59	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	27.0	145
60	Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement. JACC: Cardiovascular Interventions, 2010, 3, 920-927.	2.9	141
61	In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 37-45.	2.9	139
62	Estimated Risks for Developing Obesity in the Framingham Heart Study. Annals of Internal Medicine, 2005, 143, 473.	3.9	131
63	Free Testosterone Levels Are Associated with Mobility Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2790-2799.	3.6	130
64	Cardiovascular Risk Factors Predictive for Survival and Morbidity-Free Survival in the Oldest-Old Framingham Heart Study Participants. Journal of the American Geriatrics Society, 2005, 53, 1944-1950.	2.6	122
65	Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. European Heart Journal, 2012, 33, 1734-1741.	2.2	122
66	Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community. Circulation, 2009, 120, 2414-2420.	1.6	121
67	Validation of an Atrial Fibrillation Risk Algorithm in Whites and African Americans. Archives of Internal Medicine, 2010, 170, 1909-17.	3.8	120
68	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation, 2019, 139, 1603-1611.	1.6	115
69	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 579-590.	6.1	114
70	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 2015, 22, 1321-1327.	1.8	112
71	Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure. JAMA Cardiology, 2020, 5, 300.	6.1	104
72	Left Ventricular Hypertrophy Patterns and Incidence of Heart Failure With Preserved Versus Reduced Ejection Fraction. American Journal of Cardiology, 2014, 113, 117-122.	1.6	103

#	Article	IF	Citations
73	Electrocardiographic QRS Duration and the Risk of Congestive Heart Failure. Hypertension, 2006, 47, 861-867.	2.7	101
74	Risk assessment for incident heart failure in individuals with atrial fibrillation. European Journal of Heart Failure, 2013, 15, 843-849.	7.1	96
75	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€"A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	7.1	90
76	Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. European Heart Journal, 2012, 33, 1095-1104.	2.2	88
77	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	2.7	82
78	Transcatheter Versus Surgical AorticÂValveÂReplacement. Journal of the American College of Cardiology, 2017, 70, 439-450.	2.8	82
79	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	4.1	81
80	Reclassification Calculations for Persons With Incomplete Follow-up. Annals of Internal Medicine, 2010, 152, 195.	3.9	77
81	Prediction Models â€" Development, Evaluation, and Clinical Application. New England Journal of Medicine, 2020, 382, 1583-1586.	27.0	77
82	Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice. Circulation: Cardiovascular Interventions, 2010, 3, 327-334.	3.9	76
83	Quantifying discrimination of Framingham risk functions with different survival C statistics. Statistics in Medicine, 2012, 31, 1543-1553.	1.6	76
84	P-wave indices and atrial fibrillation: Cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal, 2015, 169, 53-61.e1.	2.7	74
85	Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. American Heart Journal, 2021, 231, 1-5.	2.7	73
86	Age Trends in Estradiol and Estrone Levels Measured Using Liquid Chromatography Tandem Mass Spectrometry in Community-Dwelling Men of the Framingham Heart Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 733-740.	3.6	71
87	Evaluation of Markers and Risk Prediction Models. Medical Decision Making, 2013, 33, 490-501.	2.4	71
88	Genetic Predisposition to Higher Blood Pressure Increases Coronary Artery Disease Risk. Hypertension, 2013, 61, 995-1001.	2.7	70
89	Net reclassification index at event rate: properties and relationships. Statistics in Medicine, 2017, 36, 4455-4467.	1.6	70
90	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology, 2019, 76, 1192.	9.0	70

#	Article	IF	Citations
91	A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis, 2012, 223, 421-426.	0.8	69
92	Trajectories of Non–HDL Cholesterol Across Midlife. Journal of the American College of Cardiology, 2019, 74, 70-79.	2.8	67
93	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation, 2016, 133, 1574-1581.	1.6	66
94	BMI vs. Waist Circumference for Identifying Vascular Risk. Obesity, 2008, 16, 463-469.	3.0	65
95	Prevalence, Clinical Correlates, and Prognosis of Discrete Upper Septal Thickening on Echocardiography: The Framingham Heart Study. Echocardiography, 2009, 26, 247-253.	0.9	65
96	Repeat Revascularization After Contemporary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 772-782.	3.9	61
97	Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community. Journal of the American Heart Association, 2013, 2, e000126.	3.7	61
98	Data monitoring committees: Promoting best practices to address emerging challenges. Clinical Trials, 2017, 14, 115-123.	1.6	61
99	Ankle–brachial index and cardiovascular risk prediction: An analysis of 11,594 individuals with 10-year follow-up. Atherosclerosis, 2012, 220, 160-167.	0.8	60
100	Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community. Circulation, 2009, 119, 1101-1107.	1.6	58
101	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	2.8	58
102	Use of Open Access Platforms for Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 1283.	7.4	57
103	Characteristics of Framingham Offspring Participants With Long-lived Parents. Archives of Internal Medicine, 2007, 167, 438.	3.8	55
104	The Role of Physicians in the Era of Predictive Analytics. JAMA - Journal of the American Medical Association, 2015, 314, 25.	7.4	55
105	Neck Circumference and the Development of Cardiovascular Disease Risk Factors in the Framingham Heart Study. Diabetes Care, 2013, 36, e3-e3.	8.6	53
106	Diet Quality, Physical Activity, Smoking Status, and Weight Fluctuation Are Associated with Weight Change in Women and Men. Journal of Nutrition, 2010, 140, 1287-1293.	2.9	51
107	A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Medical Research Methodology, 2016, 16, 148.	3.1	50
108	Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking. Circulation, 2005, 112, 1719-1727.	1.6	48

#	ARTICLE	IF	CITATIONS
109	Associations of Edge-Detected and Manual-Traced Common Carotid Intima-Media Thickness Measurements With Framingham Risk Factors. Stroke, 2011, 42, 1912-1916.	2.0	48
110	Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. Statistics in Medicine, 2014, 33, 3415-3418.	1.6	47
111	Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 474-480.	3.9	45
112	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation, 2020, 142, 827-837.	1.6	44
113	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Circulation, 2015, 132, 1404-1413.	1.6	43
114	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. JAMA Cardiology, 2019, 4, 375.	6.1	43
115	Advance Care Planning and Health Care Preferences of Community-Dwelling Elders: The Framingham Heart Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 951-959.	3.6	42
116	Genotype Prediction of Adult Type 2 Diabetes From Adolescence in a Multiracial Population. Pediatrics, 2012, 130, e1235-e1242.	2.1	42
117	Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials. Circulation: Heart Failure, 2012, 5, 742-749.	3.9	42
118	Temporal Trends in Self-Reported Functional Limitations and Physical Disability Among the Community-Dwelling Elderly Population: The Framingham Heart Study. American Journal of Public Health, 2008, 98, 1256-1262.	2.7	41
119	Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use. Circulation, 2011, 124, 1028-1037.	1.6	41
120	Application of net reclassification index to non-nested and point-based risk prediction models: a review. European Heart Journal, 2019, 40, 1880-1887.	2.2	39
121	Discrimination slope and integrated discrimination improvement â€" properties, relationships and impact of calibration. Statistics in Medicine, 2017, 36, 4482-4490.	1.6	37
122	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 435-451.	1.9	36
123	Understanding increments in model performance metrics. Lifetime Data Analysis, 2013, 19, 202-218.	0.9	32
124	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation, 2011, 41, 1010-1035.	3.4	30
125	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. JAMA - Journal of the American Medical Association, 2016, 316, 2041.	7.4	30
126	Association of Parental Obesity With Concentrations of Select Systemic Biomarkers in Nonobese Offspring. Diabetes, 2009, 58, 134-137.	0.6	29

#	Article	IF	Citations
127	Performance of current guidelines for coronary heart disease prevention: Optimal use of the Framingham-based risk assessment. Atherosclerosis, 2011, 216, 452-457.	0.8	29
128	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. Statistics in Medicine, 2011, 30, 1410-1418.	1.6	29
129	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. JAMA Cardiology, 2016, 1, 864.	6.1	29
130	Supporting open access to clinical trial data for researchers: The Duke Clinical Research Instituteâ€"Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. American Heart Journal, 2016, 172, 64-69.	2.7	28
131	Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. Journal of Pediatrics, 2016, 178, 125-129.e1.	1.8	27
132	Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 463-473.	3.9	25
133	Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study. Diabetes Care, 2013, 36, 1590-1596.	8.6	25
134	Risk Prediction With Electronic Health Records. JAMA Cardiology, 2016, 1, 976.	6.1	25
135	Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study. Journal of Hypertension, 2008, 26, 2121-2125.	0.5	23
136	A framework for the oversight and local deployment of safe and high-quality prediction models. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1631-1636.	4.4	23
137	Association of Parental Hypertension With Concentrations of Select Biomarkers in Nonhypertensive Offspring. Hypertension, 2008, 52, 381-386.	2.7	21
138	Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. Biometrical Journal, 2015, 57, 556-570.	1.0	21
139	Segment-Specific Association Between Plasma Homocysteine Level and Carotid Artery Intima-Media Thickness in the Framingham Offspring Study. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 155-161.	1.6	20
140	Variations in Common Carotid Artery Intima-Media Thickness during the Cardiac Cycle: Implications for Cardiovascular Risk Assessment. Journal of the American Society of Echocardiography, 2012, 25, 1023-1028.	2.8	20
141	What to expect from net reclassification improvement with three categories. Statistics in Medicine, 2014, 33, 4975-4987.	1.6	20
142	Asymptotic distribution of â€ AUC, NRIs, and IDI based on theory of Uâ€statistics. Statistics in Medicine, 2017, 36, 3334-3360.	1.6	20
143	Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure. Circulation: Cardiovascular Genetics, 2010, 3, 492-498.	5.1	19
144	Impact of correlation on predictive ability of biomarkers. Statistics in Medicine, 2013, 32, 4196-4210.	1.6	17

#	Article	IF	Citations
145	The Dose–Response Relationship Between Physical Activity and Cardiometabolic Health in Adolescents. American Journal of Preventive Medicine, 2021, 60, 95-103.	3.0	17
146	Efficacy of Dose Increase Among Nonresponders to Low-Dose Aripiprazole Augmentation in Patients With Inadequate Response to Antidepressant Treatment:. Journal of Clinical Psychiatry, 2012, 73, 353-357.	2.2	17
147	Aortic Root Diameter and Longitudinal Blood Pressure Tracking. Hypertension, 2008, 52, 473-477.	2.7	16
148	Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 2020, 5, 988.	6.1	16
149	Incremental Benefits of Machine Learning—When Do We Need a Better Mousetrap?. JAMA Cardiology, 2021, 6, 621.	6.1	15
150	Cross-sectional relations of urinary sodium excretion to cardiac structure and hypertrophy. The Framingham Heart Study. American Journal of Hypertension, 2004, 17, 891-896.	2.0	14
151	Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study. American Journal of Medicine, 2007, 120, 623-630.e1.	1.5	14
152	Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Atherosclerosis, 2011, 216, 174-179.	0.8	14
153	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology, 2011, 26, 313-337.	5.7	14
154	Thoroughly Modern Risk Prediction?. Science Translational Medicine, 2012, 4, 131fs10.	12.4	13
155	Validation of a Breast Cancer Risk Prediction Model Developed for Black Women. Journal of the National Cancer Institute, 2013, 105, 361-367.	6.3	13
156	Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease. Circulation: Cardiovascular Interventions, 2014, 7, 365-373.	3.9	13
157	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. JAMA Cardiology, 2016, 1, 700.	6.1	13
158	An Obesity Dietary Quality Index Predicts Abdominal Obesity in Women: Potential Opportunity for New Prevention and Treatment Paradigms. Journal of Obesity, 2010, 2010, 1-9.	2.7	12
159	Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics, 2011, 19, 615-615.	2.8	12
160	Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 664-673.	2.8	12
161	Parental Intermittent Claudication as Risk Factor for Claudication in Adults. American Journal of Cardiology, 2012, 109, 736-741.	1.6	12
162	Estimating Lifetime Risk of Developing High Serum Total Cholesterol: Adjustment for Baseline Prevalence and Single-Occasion Measurements. American Journal of Epidemiology, 2006, 165, 464-472.	3.4	11

#	ARTICLE	IF	CITATIONS
163	Performance of a Method for Identifying the Unique Dietary Patterns of Adult Women and Men: The Framingham Nutrition Studies. Journal of the American Dietetic Association, 2008, 108, 1453-1460.	1.1	10
164	Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. Journal of Hypertension, 2009, 27, 1317-1324.	0.5	10
165	Invited Commentary: Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance. American Journal of Epidemiology, 2012, 176, 187-189.	3.4	10
166	Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 106.	6.8	10
167	Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology, 2011, 64, e1-e22.	5.0	9
168	Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. Cardiovascular Revascularization Medicine, 2017, 18, 169-176.	0.8	9
169	Deriving Real-World Insights From Real-World Data: Biostatistics to the Rescue. Annals of Internal Medicine, 2018, 169, 401.	3.9	9
170	Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer–Norfolk Cohort–Invited Commentary. Archives of Internal Medicine, 2008, 168, 1216.	3.8	8
171	Caution Is Needed in the Interpretation of Added Value of Biomarkers Analyzed in Matched Case Control Studies. Clinical Chemistry, 2012, 58, 1176-1178.	3.2	8
172	RE: Net Risk Reclassification P Values: Valid or Misleading?. Journal of the National Cancer Institute, 2014, 107, dju355-dju355.	6.3	8
173	Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3729.	2.4	8
174	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	2.7	7
175	Statistical methods for building better biomarkers of chronic kidney disease. Statistics in Medicine, 2019, 38, 1903-1917.	1.6	7
176	An aetiology–based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH–HF) trial. ESC Heart Failure, 2021, 8, 1263-1273.	3.1	7
177	Algorithms for Assessing Cardiovascular Risk in Women. JAMA - Journal of the American Medical Association, 2007, 298, 173.	7.4	6
178	Measuring Carotid Artery Intima-Media Thickness: Simplicity Versus Complexity?. Journal of the American Society of Echocardiography, 2012, 25, 101-104.	2.8	6
179	Prostate-specific Antigen Velocity: New Methods, Same Results, Still No Evidence of Clinical Utility. European Urology, 2013, 64, 394-396.	1.9	6
180	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. Statistics in Medicine, 2019, 38, 3817-3831.	1.6	6

#	Article	IF	Citations
181	Cross-Sectional Relations of Lipid Concentrations to Left Ventricular Structural Attributes. American Journal of Cardiology, 2010, 105, 1297-1299.	1.6	5
182	Circulating plasma cholesteryl ester transfer protein activity and blood pressure tracking in the community. Journal of Hypertension, 2011, 29, 863-868.	0.5	5
183	Comparison of Academic and Nonacademic Sites in Multi-Center Clinical Trials. Journal of Clinical Psychopharmacology, 2012, 32, 65-68.	1.4	5
184	Pencina et al. Respond to "The Incremental Value of New Markers" and "Clinically Relevant Measures? A Note of Caution". American Journal of Epidemiology, 2012, 176, 492-494.	3.4	5
185	Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patientsâ€"Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREHâ€HF) randomized clinical trial. Annals of Noninvasive Electrocardiology, 2021, 26, e12887.	1.1	5
186	Response to â€˜Net reclassification improvement and decision theoryâ€™ by Vickers <i>et al</i>.. Statistics in Medicine, 2009, 28, 526-528.	1.6	3
187	Authors' response to comments. Statistics in Medicine, 2017, 36, 4511-4513.	1.6	3
188	Clinical Trials in the 21st Century â€" Promising Avenues for Better Studies. , 2022, 1, .		3
189	Response to Letter Regarding Article, â€œHyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Diseaseâ€. Circulation, 2015, 132, e203.	1.6	2
190	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. Circulation, 2017, 136, 1860-1862.	1.6	2
191	Microsimulation model to predict incremental value of biomarkers added to prognostic models. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1382-1385.	4.4	2
192	Estimation of Risk for Initial Atherosclerotic Cardiovascular Disease Events. Circulation, 2016, 134, 1792-1793.	1.6	1
193	Open Access Platforms for Sharing Clinical Trial Dataâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 316, 666.	7.4	1
194	Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. American Heart Journal, 2019, 218, 32-45.	2.7	1
195	Singleâ€number summary and decision analytic measures can happily coexist. Statistics in Medicine, 2019, 38, 499-500.	1.6	1
196	Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk. Journal of Hypertension, 2013, 31, 1001-1009.	0.5	0
197	Rejoinder. Clinical Trials, 2017, 14, 126-127.	1.6	0
198	Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up â€" subanalysis of the TELEREHabilitation in Heart Failure Patients randomized clinical trial. Archives of Medical Science, 2021, 18, 293-306.	0.9	0

#	Article	IF	Citations
199	Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fractionâ€"Subanalysis of the TELEREH-HF Randomized Clinical Trial. Journal of Clinical Medicine, 2022, 11, 1844.	2.4	0